Büssing A, Stein G M, Pfüller U
Krebsforschung Herdecke, Department of Applied Immunology, Communal Hospital Herdecke, D-58313 Herdecke, Germany.
Cell Death Differ. 1998 Mar;5(3):231-40. doi: 10.1038/sj.cdd.4400343.
As reported previously by our group, among the toxic proteins from Viscum album L. only the mistletoe lectins (MLs) induce the apoptotic killing pathway in human lymphocytes. Although one may expect a homogenous distribution of carbohydrate domains on cell surface receptors for the carbohydrate binding B chains of the toxic protein, the sensitivity of cells to these B chains obviously differ. Here we report a selective killing of CD8+ CD62Llo cells from healthy individuals by the galNAc-specific ML III (and RCA60, which binds to gal and galNAc), while the gal-specific ML I was less effective. This selective killing is not sufficiently explained by protein synthesis inhibition alone, since this subset was not affected by other ribosome inhibiting proteins such as the lectin from Ricinus communis (RCA120), lectin from Abrus precatorus (APA), abrin A, and inhibitors of RNA, DNA and/or protein synthesis such as actinomycin D, mitomycin C, and cycloheximide. We conclude that CD8+ cells with 'memory' phenotype (CD62Llo) are more sensitive to the ML III-mediated killing than their CD8+ CD62Lhi counterparts, CD4+ T cells, and CD19+ B cells. These cells probably express a distinct receptor with galNAc domains that is missing or not active on CD8+ cells with a 'naive' phenotype.
正如我们小组之前所报道的,在欧洲槲寄生的毒性蛋白中,只有槲寄生凝集素(MLs)能诱导人淋巴细胞中的凋亡杀伤途径。尽管人们可能预期毒性蛋白碳水化合物结合B链的细胞表面受体上碳水化合物结构域分布均匀,但细胞对这些B链的敏感性显然不同。在此我们报告,半乳糖胺特异性的ML III(以及与半乳糖和半乳糖胺结合的RCA60)可选择性杀伤健康个体的CD8+ CD62Llo细胞,而半乳糖特异性的ML I效果较差。这种选择性杀伤不能仅通过蛋白质合成抑制来充分解释,因为该亚群不受其他核糖体抑制蛋白(如蓖麻凝集素(RCA120)、相思子凝集素(APA)、相思子毒素A)以及RNA、DNA和/或蛋白质合成抑制剂(如放线菌素D、丝裂霉素C和环己酰亚胺)的影响。我们得出结论,具有“记忆”表型(CD62Llo)的CD8+细胞比其CD8+ CD62Lhi对应细胞、CD4+ T细胞和CD19+ B细胞对ML III介导的杀伤更敏感。这些细胞可能表达一种具有半乳糖胺结构域且在具有“幼稚”表型的CD8+细胞上缺失或无活性的独特受体。